Lilly settles Zyprexa suit with S. Carolina
Eli Lilly and Co. has agreed to settle the State of South Carolina’s lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
Home » Search
Search Results
4,417 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Senate bill doesn’t fund Rolls-Royce jet engine
The measure holds potential bad news for Indianapolis engine maker Rolls-Royce because it does not contain funding for a key
jet engine the company produces, but lawmakers are expected to restore funding when the Senate and House combine bills into
a final version.IT consultant up for tax abatement
A city board this week will consider tax abatements worth about $47,000 over six years for Indianapolis-based IT consultant
Apparatus Inc., which is moving its headquarters to the former WFYI building at 1401 N. Meridian St.Overhaul of teacher training threatens college budgets
Proposed changes to teacher licensing rules are a threat in the eyes of most deans of Indiana’s colleges of education—both
to the quality
of
teacher training and to the budgets of the colleges.Connecticut gets $25 million from Zyprexa lawsuit
Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.Local Better Business Bureau names new leader
William J. Thomas has been named president of the Better Business Bureau of Central Indiana, the organization announced Monday.
Lilly’s win in Evista patent case crucial, analyst says
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.Judge upholds Lilly’s Evista patent
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.Bartering booms during recession
In a recession, cash is a commodity few small businesses can spare. That’s why more businesses are trading goods and services without exchanging cash.
Lilly agrees to settle more state Zyprexa suits
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.Lilly sells constipation drug to Adolor
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.Lilly: Alimta improves survival in lung cancer
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care. Alimta is used as a “maintenance
therapy” for patients whose disease has not progressed after chemotherapy. In a study involving 663 patients, Lilly said patients
treated with Alimta and best available care lived for an average of 13.4 months. Those treated with best care and a placebo
lived for an average of 10.6 months.Lilly: Alimta improves lung-cancer survival time
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.Lilly revises playbook in effort to score more ‘touchdowns’
The drugmaker has successfully moved experimental drugs into position to win approval by regulators. But only once in the
last four years has a new drug actually made it to market—the industry’s equivalent of getting
across the goal line.Local health care industry tries to capitalize on migraine headaches
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.UPDATE: Pipeline challenges force Lilly restructuring moves
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.Lilly as an employment destination
Eli Lilly and Co. has experienced a string of setbacks in recent years. Is it still a good place to work?
Lilly reorganization to cut 5,500 positions over 2 years
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.United Way scales back fund-raising goal
United Way of Central Indiana recently announced a fund-raising goal of $39 million. That’s less than the goal of
$40 million set last year, when fund raising fell short, ending at $38.8 million.Study weakens Lilly’s fight against price controls
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.